Cancer Vaccine GMP Manufacturing

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• TCR Modified T Cell Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• TCR-Like Antibody Services
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• Bispecific TCR Development
• Drug Discovery Assay for Cytokine Storm Inhibition
• End-to-end CAR Hybrid TCR-T Cell Therapy Development
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing

Cancer Vaccine GMP Manufacturing

The vaccine is a biological agent that enhances immunity to a particular disease. Over time, it has evolved from traditional prophylactic uses to more complicated therapeutic products. The cancer vaccine development is a pathway from discovery research to clinical evaluation of putative protective antigens. The process is unique, capital intensive and risky. Given the significance of safety with biologics, the vaccine industry is highly valued.

Fig.1 Life cycle of modern vaccine development. (Kaufmann, 2014)

There are a lot of challenges in the field of cancer vaccine development. it is essential to be in balance with cost, risks, and benefits besides finding safe and effective antigens, adjuvants, and delivery systems. Today, Creative Biolabs makes efforts to meet the steadily growing demands for novel cancer vaccines and accelerate vaccine design, development, and manufacturing through international collaboration and continuous innovation of technologies.

Cancer Vaccine Development at Creative Biolabs

Development of every vaccine starts at the exploratory stage. The goal of therapeutic cancer vaccines is to induce immunity activities against tumor-associated antigens (TAAs), which fall into two categories: tumor-specific shared antigens and tumor-specific unique antigens.

Cancer vaccine developments can be divided into two stages, pre-clinical and clinical development. Pre-clinical studies comprise laboratory and animal experiments. In the clinical stage, the vaccines are tested in humans and this process takes four phases and lasts for many years. Currently, we hope to introduce the following services to allow for a more streamlined and profitable vaccine development.

Creative Biolabs supports cancer vaccine development in both the pre-clinical and clinical phases. Our unique combination of expertise makes us an ideal partner to facilitate clients’ vaccine research from the identification of potential targets, analysis of immune responses, to assessment in animal models.

GMP Manufacturing at Creative Biolabs

Cancer vaccines are made in the same way as other biologicals, but with higher standards, to ensure the purity and quality of final products. Every step from the beginning must be confirmed and the whole process of manufacture must be carried out in a clean, safe, and controlled environment.

In Creative Biolabs, cancer vaccines are prepared following Good Manufacturing Practices (GMP) and our cleanrooms are a part of GMP regulations for vaccine development. The circumstance of humidity, air, and temperature in this room are controlled along with the number of entering people simultaneously. According to the requirements, we can meet three GMP standards, including ISO, EU, and US-FDA, and we can deal with different issues in vaccine production.

1. GMP issues for upstream processing

General GMP concerns for upstream; Raw material preparation; Cell culture; Virus culture; Inactivation of microorganisms.

1. GMP issues for downstream processing

General GMP concerns for downstream; (ultra) Filtration techniques; (ultra) Centrifugation techniques; Sterile filtration and aseptic processing.

Highlights from Creative Biolabs

1. Guarantee: each cancer vaccine project is guaranteed by a SOP.
2. Comprehensive solutions: a complete pipeline with flexible options is provided for clients.
3. Top facilities & cleanrooms: every step is operated under the best conditions in an efficient manner.
4. Rich experience: our staffs have more than 10 years of experience in vaccine programs.

Vaccination remains the most cost-effective public health intervention, whose benefits extremely outweigh the costs. Here, Creative Biolabs can offer multiple products and services in the process development of cancer vaccines, GMP manufacturing, and analytical testing, as well as assist clients in pre-clinical and clinical research to support vaccine commercialization.

For more information on the solutions of vaccine-related services, please contact us by e-mail.

Reference

1. Kaufmann, S.H.; et al. Challenges and responses in human vaccine development. Curr Opin Immunol. 2014, 28: 18-26.